Medical and surgical aspects of parathyroidectomy  by Fukagawa, Masafumi et al.
Kidney International, Vol. 56, Suppl. 73 (1999), pp. S-65–S-69
Medical and surgical aspects of parathyroidectomy
MASAFUMI FUKAGAWA, YOSHIHIRO TOMINAGA, MASAFUMI KITAOKA, TAKATOSHI KAKUTA,
and KIYOSHI KUROKAWA
Division of Nephrology and Clinical Research Center, Tokyo Teishin Hospital, Tokyo; Division of Transplantation Surgery,
Nagoya Second Red Cross Hospital, Nagoya; Division of Endocrinology and Metabolism, Showa General Hospital, Kodaira;
and Division of Nephrology, Tokai University School of Medicine, Isehara, Japan
Medical and surgical aspects of parathyroidectomy. A more ionized calcium is needed to suppress PTH secretion [3].
logical approach to the management of the chronic dialysis Furthermore, parathyroid glands with nodular hyperpla-
patient with parathyroid hyperplasia has become possible sia cells express more Ki67 (a kind of proliferative nu-thanks to recent progress in cellular and molecular analysis of
clear antigen), retinoblastoma protein, and cyclin D1surgically removed parathyroid glands and accumulation of
than do cells in diffuse hyperplasia [4]. Apparently inclinical experience. When one or more parathyroid glands
progress to the stage of nodular hyperplasia, it is usually diffi- nodular hyperplasia the growth potential of parathyroid
cult to control PTH secretion even by calcitriol pulse therapy. cells is higher than in diffuse hyperplasia. As recently
For such patients, we have developed two new therapeutic
shown by using X chromosome inactivation with PCRapproaches, i.e., selective percutaneous ethanol injection ther-
and restriction enzyme digestion, monoclonal prolifera-apy (PEIT) and direct calcitriol injection therapy, in combina-
tion with medical therapy. For optimal selection of therapeutic tion may be present irrespective of the size of the nodule
modalities it is indispensable to evaluate the degree and stage [5]. By contrast, cells in parathyroid glands with diffuse
of parathyroid hyperplasia. For successful management, pre- hyperplasia are always of polyclonal origin.vention of nodular hyperplasia is the most important strategy.
Additional information was derived from the analysis
of transplanted fragments of parathyroid glands. As
shown in Fig. 1 (right), in patients undergoing total para-Hyperplasia of parathyroid glands is one of the charac-
thyroidectomy with autotransplantation, surgeons selectteristic features of very severe secondary hyperparathy-
fragments for transplantation from the smallest glandroidism in chronic dialysis patients [1]. We have been
[6]. Nevertheless, recurrence of hyperparathyroidism isaccumulating basic and clinical data on parathyroid hy-
sometimes encountered. A large-scale follow-up studyperplasia in the last l0 years. Such information has pro-
revealed that the recurrence rate was significantly lessvided us with more options of treatment, either medical
frequent than from diffuse hyperplasia. The cells in theor surgical, and more logical approaches to these patients.
fragments of patients who had recurrence of hyperpara-
thyroidism exhibited high growth potential comparable
WHAT HAVE WE LEARNED FROM SURGICAL to that of cells in nodular hyperplasia, as assessed by
PARATHYROIDECTOMY? flow cytometry [7].
Large parathyroid glands in dialysis patients usually
show asymmetrical enlargement and nodule formation.
CELLULAR PATHOGENESIS OFThere are two types of parathyroid hyperplasia, diffuse
PARATHYROID HYPERPLASIAhyperplasia and nodular hyperplasia; usually nodules are
surrounded by a fibrous capsule. Nodular hyperplasia is What are the mechanisms underlying such abnormali-
the more advanced type of hyperplasia and is seen more ties of parathyroid cells in nodular hyperplasia? We ex-
often in large glands. The characteristics of cells in nodu- amined the density of vitamin D receptors in these cells
lar and diffuse hyperplasia are strikingly different [2]. and found that cells in nodular hyperplasia had a signifi-
In nodular hyperplasia the sigmoidal curve, relating cantly lower density of vitamin D receptors than those
PTH secretion to the concentration of ionized calcium, in diffuse hyperplasia [8]. A significant negative relation-
is shifted to the right, i.e., a higher concentration of ship was found between Vitamin D receptor density and
the number of PCNA positive cells or gland weight [9].
Recently, a decrease of calcium sensing receptors in nod-Key words: chronic dialysis, parathyroid hyperplasia, parathyroid hor-
mone, percutaneous ethanol injection therapy. ular hyperplasia has also been demonstrated [10].
Parathyroid hyperplasia progresses from diffuse to nod- 1999 by the International Society of Nephrology
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Fig. 1. Selective PEIT and surgical parathy-
roidectomy. In selective PEIT (left), glands
with nodular hyperplasia are destroyed by eth-
anol injection (X) and the other glands with
diffuse hyperplasia are controlled by medical
therapy. In the surgical parathyroidectomy
(right), all glands are excised (X) and frag-
ments from the smallest gland (\) are trans-
planted.
ular hyperplasia. Some cells with more pronounced reduc- thyroid glands revealed that most of the parathyroid
glands weighing more than 0.5 g exhibited nodular hyper-tion of vitamin D receptor and calcium-sensing receptor
in areas of diffuse hyperplasia begin to proliferate more plasia [12].
One can predict the existence of nodular hyperplasiavigorously leading to formation of individual nodules
and finally to nodular hyperplasia. In very severe cases, by estimating gland size, which can be done most easily
by ultrasonography. The shape of the enlarged glandsone of the nodules outgrow the others so as to occupy
the whole gland, forming a single nodule. This is the can also be assessed by the latest generation of ultrasono-
graphic devices and this also provides helpful informa-most advanced type of parathyroid hyperplasia in uremia.
tion. In addition, blood supply to the glands can also
serve as a marker for nodular hyperplasia. Blood supply
CLINICAL IMPLICATIONS OF
to enlarged parathyroid glands can be detected by color
PARATHRYOID HYPERPLASIA
Doppler ultrasonography, especially using the power
As can be deduced from the pathogenesis, parathyroid mode [13]. A recent preliminary report suggests that
cells in parathyroid glands with nodular hyperplasia are most of the enlarged glands with detectable blood supply
usually resistant to medical therapy. Accordingly, for within the gland exhibited nodular hyperplasia. Quanti-
optimal selection of therapeutic modalities, it is critical tative evaluation of blood supply is mandatory for pre-
to distinguish between diffuse and nodular hyperplasia. cise recognition of nodular hyperplasia.
Our experience with calcitriol pulse therapy shows
that one useful index may be the size of the gland. In
MANAGEMENT OF PATIENTS WITHpatients who have small parathyroid gland(s), PTH se-
NODULAR HYPERPLASIAcretion was easily suppressed by calcitriol pulse therapy,
and subsequently the patients were well controlled by How can one manage patients with nodular hyperpla-
sia? Needless to say, prevention of nodular hyperplasiaconventional oral vitamin D therapy. By contrast, PTH
was not controlled in the long term in patients who had is the best strategy. For this purpose, control of serum
phosphate seems very important. A high concentrationrelatively large parathyroid gland(s). This observation
suggests that larger glands are more resistant to calcitriol of phosphate directly stimulates synthesis and secretion
of PTH. Such stimulation was more evident in glandsthan smaller glands. In our experience, patients with at
least one gland larger than 0.5 cm3, or l cm in diameter, with diffuse than with nodular hyperplasia [14]. These
data suggest that the sensing mechanism for phosphateare usually refractory to calcitriol pulse therapy in the
long term [11]. Independently, it has also been shown is maintained only in cells in areas of diffuse hyperplasia.
Thus, phosphate control is important for the preventionthat transplanted parathyroid fragments derived from
glands weighing more than 0.5 g relapse frequently [12]. of parathyroid hyperplasia especially in the early phase
of secondary hyperparathyroidism.Since gland size and weight correlate very well, this
size seems to be critical to predict resistance to medical Until recently, patients with nodular hyperplasia have
been treated by calcitriol pulse therapy which failed totherapy. A histologic study of surgically removed para-
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Fig. 2. Color Doppler imaging of parathyroid
hyperplasia (transverse, left; sagittal, right).
(A) Ample blood supply was demonstrated in
the markedly enlarged parathyroid gland with
power Doppler mode. (B) Blood supply inside
of the gland disappeared after the first ethanol
injection. Some nodules surrounded by the
blood supply to the surface of the gland were
recognized.
effectively suppress PTH and result in hypercalcemia in and the remaining glands with diffuse hyperplasia are
controlled by medical therapy (Fig. 1). Thanks to techno-most cases. Only in advanced cases was surgical parathy-
roidectomy considered. For such patients, a new strategy logical progresses, we can now perform PEIT more effi-
ciently and safely than ever.has recently been established i.e., selective percutaneous
ethanol injection therapy (PEIT) of the parathyroid The indication for PEIT is almost the same as that
for surgical parathyroidectomy, i.e., high turnover bonegland [15]. This technique is no longer only an alternative
to surgical parathyroidectomy, but serves also as a pow- disease due to high PTH, marked parathyroid hyperpla-
sia, and resistance to medical therapy. In such patientserful adjunct to medical therapy. As shown in Figure 1,
in surgical parathyroidectomy all glands are excised and all glands larger than 0.5 cm3 should be destroyed to
achieve effective control of parathyroid function. Pa-fragments taken from the smallest gland are trans-
planted. By contrast, in selective PEIT, all glands with tients with one or two enlarged glands with nodular hy-
perplasia are good candidates for this therapy.nodular hyperplasia are selectively destroyed by ethanol
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Fig. 3. Currently available therapeutic modal-
ities for hyperparathyroidism in dialysis pa-
tients. There are many options for treatment
depending on PTH levels and the degrees of
parathyroid hyperplasia. For patients with one
or two enlarged glands with nodular hyperpla-
sia, “selective PEIT” or “direct calcitriol injec-
tion” can be the choice of treatment in combi-
nation with medical therapy.
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